TruAlt Bioenergy Q3 FY26 results: PAT swings to profit at Rs 69.2 cr

Related Party TransactionsResults View source PDF Explain this filing

TRUALT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.4%Reaction day

₹406.80

prior close

₹386.55

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-6.7% vs market

Other Agricultural Products peers, median of 52sector+0.5%-5.9% vs sector

On the reaction day the stock moved 6.7 pts less than Nifty Microcap 250 and 5.9 pts less than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.6

10m

-4.3

15m

-5.1

30m

-3.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.4+1.3-6.7+0.5-5.9

Next day

+0.0+0.3-0.3-0.5+0.5

+5.7-0.5+6.2-0.3+6.0

+7.3+2.1+5.2+0.5+6.7

+8.8+3.1+5.7+0.8+8.1

+8.2+2.6+5.6+0.0+8.2

+3.2+0.6+2.7+0.1+3.1

15d

-0.3-1.4+1.2-2.1+1.9

-7.4-6.9-0.4-5.9-1.5

+3.4-7.7+11.1-7.3+10.7

+22.4+7.0+15.4+2.3+20.1

UpDownMarket · Nifty Microcap 250Sector · Other Agricultural Products peers, median of 52Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

TruAlt Bioenergy reported consolidated Q3 FY26 revenue of Rs 713.24 cr (up from Rs 415.11 cr YoY) and PAT of Rs 69.19 cr, swinging from a loss of Rs 37.94 cr in Q3 FY25. 9M FY26 revenue rose to Rs 1,131.99 cr with PAT of Rs 35.92 cr. Auditor N M Raiji issued an unmodified limited review. The company also announced a JV with Sumitomo Corporation for compressed biogas plants, a Honeywell partnership for sustainable aviation fuel, and appointed a new Company Secretary. The company listed on NSE and BSE in October 2025 after a 75x oversubscribed IPO.

Likely market impact

Strong Q3 turnaround and new partnerships in CBG and SAF signal growth, though partial capacity use may cap near-term gains.